Follow
Tumor
Tumor: is an abnormal mass of tissue that may be solid or fluid-filled. A tumor is not the same as cancer. Although, some tumors can develop into cancers. A tumor is a kind of lump or swelling and does not necessarily pose a health threat.
-
OCT 29, 2014 | 1:30 PM
Patient-derived xenograft (PDX) models can recapitulate patient tumor histopathology, mutational status, gene expression patterns, and drug response with remarkable fidelity. At The Jackson L...Speaker: Walter Ausserer, PhDOCT 29, 2014 | 1:30 PM
Tumor cells often display fundamental changes in metabolism and increase their uptake of nutrients to meet the increased bioenergetic demands of proliferation. Glucose and glutamine are two m...Speaker: Mei Kong, PhDOCT 29, 2014 | 12:00 PM
Obesity is associated with an aggressive subtype of breast cancer called basal-like breast cancer (BBC). Using C3(1)-TAg mice, a genetically engineered mouse model that resembles human BBC, w...Speaker: Liza Makowski, PhDOCT 29, 2014 | 12:00 PM
DNASTAR offers an integrated suite of software for assembling and analyzing sequence data from all major next-generation sequencing platforms. The software supports a variety of key workflows...Speaker: Kerri PhillipsOCT 29, 2014 | 10:30 AM
The comprehensive, multidimensional molecular characterization of tumors and the individuals in which they have developed is transforming cancer definition, diagnosis, treatment, and preventi...Speaker: Kenneth Buetow, PhD, FACMIOCT 29, 2014 | 6:00 AM
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...Speaker: Kelli Bramlett, M.S.OCT 29, 2014 | 6:00 AM
The modern era of Precision Medicine requires targeted delivery of molecular inhibitors that control key processes in disease pathways. PARP (Poly ADP Ribose Polymerase) plays a crucial role...Speaker: Srinivas (Sri) Sridhar, PhDSEP 24, 2014 | 12:00 PM
Professor Stockwell will discuss the discovery of ferroptosis, a novel model of regulated but non-apoptotic cell death. He will describe how some tumors are sensitized to ferroptosis and may...SEP 24, 2014 | 11:00 AM
This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus rep...SEP 16, 2014 | 9:30 AM
Late-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. Th...Speaker: Nickolay Khazanov, PhDSEP 10, 2014 | 10:00 AM
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...AUG 21, 2014 | 11:30 AM
The comprehensive, multidimensional molecular characterization of tumors and the individuals in which they have developed is transforming cancer definition, diagnosis, treatment, and preventi...Speaker: Kenneth Buetow, PhD, FACMIPresented at: Genetics and Genomics Virtual Event Series 2014
AUG 20, 2014 | 10:45 AM
A recent publication in Nature Genetics1 analyzed TCGA data, and classified solid tumors into two mutually exclusive classes: C class tumors, driven by copy number alterations; and M class tu...AUG 20, 2014 | 8:45 AM
The flexibility of the BioMark Real-Time PCR System, allow us to preform genetic research using different types of nano-fluidic (48.48 or 96.96) chips setup, in the thermal cycle of these chi...AUG 20, 2014 | 8:00 AM
One of the hallmarks of human cancers is genetic instability. My colleagues and I recently identified a remarkable association between human papillomavirus (HPV) and genomic structural variat...MAY 30, 2014 | 7:30 AM
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...Speaker: Kelli Bramlett and Jeoffrey SchagemanMAY 29, 2014 | 7:30 AM
One of the major challenges to oncology based drug discovery and development has been the limited or incremental impact that many targeted agents have exhibited in the clinic. Understanding a...Speaker: Emma Bowden, PhDMAY 28, 2014 | 10:30 AM
Traditional testing methods for monoclonal protein in Plasma Cell Dyscrasias correctly identify a majority of patients. However, limitations in these methods can cause patients to be missed...Speaker: Richard O'Hara, PhDMAY 28, 2014 | 6:00 AM
For the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology -- if it is negative, women are rescreen in three years and if po...Speaker: Julia Engstrom-Melnyk, PhDMAR 20, 2014 | 10:00 AM
With a rising prevalence recently exceeding 1%, autism spectrum disorder (ASD) has become a pressing public health issue. Crucial hurdles on the way to targeted treatments are (i) the relianc...MAR 19, 2014 | 1:00 PM
The Willerth lab investigates how to engineer neural tissue by combining pluripotent stem cells, controlled drug delivery and biomaterial scaffolds. When generating these replacement tissues,...FEB 19, 2014 | 10:00 AM
Making precision cancer care a future reality requires novel approachesto finding treatment targets in cancers. Single-gene assays currently performed in clinical research laboratories are in...Speaker: Christopher Corless, MD, PhDFEB 19, 2014 | 9:00 AM
Genome sequencing technologies have enabled a rapid expansion into understanding cancer biology, drug development, and treatment resistance. Research in our laboratory has focused on the app...Speaker: Milan Radovich, PhDFEB 05, 2014 | 5:00 PMC.E. CREDITS
This presentation mainly includes 4 sections, the first one: introduction for CFDA/FDA GLP Regulation and analysis the difference. The second one: introduction of the most important responsi...Speaker: Xueying Pan, MS, PhD CandidatePresented at: Laboratory Animal Sciences Virtual Event Series 2014
OCT 29, 2014 | 1:30 PM
Patient-derived xenograft (PDX) models can recapitulate patient tumor histopathology, mutational status, gene expression patterns, and drug response with remarkable fidelity. At The Jackson L...
Speaker:
Walter Ausserer, PhD
OCT 29, 2014 | 1:30 PM
Tumor cells often display fundamental changes in metabolism and increase their uptake of nutrients to meet the increased bioenergetic demands of proliferation. Glucose and glutamine are two m...
Speaker:
Mei Kong, PhD
OCT 29, 2014 | 12:00 PM
Obesity is associated with an aggressive subtype of breast cancer called basal-like breast cancer (BBC). Using C3(1)-TAg mice, a genetically engineered mouse model that resembles human BBC, w...
Speaker:
Liza Makowski, PhD
OCT 29, 2014 | 12:00 PM
DNASTAR offers an integrated suite of software for assembling and analyzing sequence data from all major next-generation sequencing platforms. The software supports a variety of key workflows...
Speaker:
Kerri Phillips
OCT 29, 2014 | 10:30 AM
The comprehensive, multidimensional molecular characterization of tumors and the individuals in which they have developed is transforming cancer definition, diagnosis, treatment, and preventi...
Speaker:
Kenneth Buetow, PhD, FACMI
OCT 29, 2014 | 6:00 AM
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...
Speaker:
Kelli Bramlett, M.S.
OCT 29, 2014 | 6:00 AM
The modern era of Precision Medicine requires targeted delivery of molecular inhibitors that control key processes in disease pathways. PARP (Poly ADP Ribose Polymerase) plays a crucial role...
Speaker:
Srinivas (Sri) Sridhar, PhD
SEP 24, 2014 | 12:00 PM
Professor Stockwell will discuss the discovery of ferroptosis, a novel model of regulated but non-apoptotic cell death. He will describe how some tumors are sensitized to ferroptosis and may...
SEP 24, 2014 | 11:00 AM
This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus rep...
SEP 16, 2014 | 9:30 AM
Late-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. Th...
Speaker:
Nickolay Khazanov, PhD
SEP 10, 2014 | 10:00 AM
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
AUG 21, 2014 | 11:30 AM
The comprehensive, multidimensional molecular characterization of tumors and the individuals in which they have developed is transforming cancer definition, diagnosis, treatment, and preventi...
Speaker:
Kenneth Buetow, PhD, FACMI
Presented at: Genetics and Genomics Virtual Event Series 2014
AUG 20, 2014 | 10:45 AM
A recent publication in Nature Genetics1 analyzed TCGA data, and classified solid tumors into two mutually exclusive classes: C class tumors, driven by copy number alterations; and M class tu...
AUG 20, 2014 | 8:45 AM
The flexibility of the BioMark Real-Time PCR System, allow us to preform genetic research using different types of nano-fluidic (48.48 or 96.96) chips setup, in the thermal cycle of these chi...
AUG 20, 2014 | 8:00 AM
One of the hallmarks of human cancers is genetic instability. My colleagues and I recently identified a remarkable association between human papillomavirus (HPV) and genomic structural variat...
MAY 30, 2014 | 7:30 AM
As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing...
Speaker:
Kelli Bramlett and Jeoffrey Schageman
MAY 29, 2014 | 7:30 AM
One of the major challenges to oncology based drug discovery and development has been the limited or incremental impact that many targeted agents have exhibited in the clinic. Understanding a...
Speaker:
Emma Bowden, PhD
MAY 28, 2014 | 10:30 AM
Traditional testing methods for monoclonal protein in Plasma Cell Dyscrasias correctly identify a majority of patients. However, limitations in these methods can cause patients to be missed...
Speaker:
Richard O'Hara, PhD
MAY 28, 2014 | 6:00 AM
For the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology -- if it is negative, women are rescreen in three years and if po...
Speaker:
Julia Engstrom-Melnyk, PhD
MAR 20, 2014 | 10:00 AM
With a rising prevalence recently exceeding 1%, autism spectrum disorder (ASD) has become a pressing public health issue. Crucial hurdles on the way to targeted treatments are (i) the relianc...
MAR 19, 2014 | 1:00 PM
The Willerth lab investigates how to engineer neural tissue by combining pluripotent stem cells, controlled drug delivery and biomaterial scaffolds. When generating these replacement tissues,...
FEB 19, 2014 | 10:00 AM
Making precision cancer care a future reality requires novel approachesto finding treatment targets in cancers. Single-gene assays currently performed in clinical research laboratories are in...
Speaker:
Christopher Corless, MD, PhD
FEB 19, 2014 | 9:00 AM
Genome sequencing technologies have enabled a rapid expansion into understanding cancer biology, drug development, and treatment resistance. Research in our laboratory has focused on the app...
Speaker:
Milan Radovich, PhD
FEB 05, 2014 | 5:00 PM
C.E. CREDITS
This presentation mainly includes 4 sections, the first one: introduction for CFDA/FDA GLP Regulation and analysis the difference. The second one: introduction of the most important responsi...
Speaker:
Xueying Pan, MS, PhD Candidate
Presented at: Laboratory Animal Sciences Virtual Event Series 2014